Abnormal, abnormality, abnormalities - see also Anomaly
  lung shadow 793.19
  Mantoux test 795.51
  product of conception NEC 631.8
  pulmonary
    artery 747.39
    radiological examination 793.99
    lung (field) 793.19
Absence (organ or part) (complete or partial)
  artery (congenital) (peripheral) NEC (see also Anomaly, peripheral vascular system) 747.60
    brain 747.81
    pulmonary 747.31
  joint, congenital NEC 755.8 (acquired) (following prior explantation of joint prosthesis) (with or without presence of antibiotic-impregnated cement spacer) NEC V88.29
    congenital NEC 755.8
    hip V88.21
    knee V88.22
  pulmonary
    artery 747.31
    trunk 747.31
Acroangiodermatitis 448.9
Adenocarcinoma (M8140/3) - see also Neoplasm, by site, malignant
  apocrine (M8401/3)
    unspecified site 173.99
  ceruminous (M8420/3) 173.29
Adhesion(s), adhesive (postinfectional) (postoperative)
  bladder (sphincter) 596.89
  perivesical 596.89
  vesical 596.89
  vitreomacular adhesion 379.27
Admission (encounter)
  for
    aftercare (see also Aftercare) V58.9
      orthopedic V54.9
        following explantation of joint prosthesis (for joint prosthesis insertion) (staged procedure) V54.82
      therapy
        long-term (current) (prophylactic) drug use NEC V58.69
          bisphosphonates V58.68
          methadone for pain control V58.69
    Aftercare V58.9
      following surgery NEC V58.49
        joint replacement V54.81
          explantation of prosthesis (staged procedure) V54.82
          replacement V54.81
        orthopedic V54.9
          following joint replacement V54.81
            explantation of prosthesis (staged procedure) V54.81
            replacement V54.81
Agenesis - see also Absence, by site, congenital
  artery (peripheral) NEC (see also Anomaly, peripheral vascular system) 747.60
  pulmonary 747.31
  pulmonary
    artery 747.31
    trunk 747.31
AIPHI (acute idiopathic pulmonary hemorrhage in infants (over 28 days old)) 786.31
Air
  leak (lung) (pulmonary) (thorax) \textit{512.84}
  persistent \textit{512.84}
  postoperative \textit{512.2}
Allergy, allergic (reaction) \textit{995.3}
  anaphylactic \textit{reaction or} shock \textit{995.0}
  due to food - see Anaphylactic \textit{reaction or} shock, due to, food
  angioedema \textit{995.1}
  serum (prophylactic) (therapeutic) \textit{999.59}
  anaphylactic \textit{reaction or} shock \textit{999.49}
  shock (anaphylactic) (due to adverse effect of correct medicinal substance
  properly administered) \textit{995.0}
  food - see Anaphylactic \textit{reaction or} shock, due to, food
  from
  administration of blood and blood products \textit{999.41}
  anaphylactic \textit{999.4}
  immunization \textit{999.42}
  serum NEC \textit{999.49}
Alpha thalassemia \textit{282.43}
Alveolar capillary block syndrome \textit{516.64}
Alveolitis
  fibrosing (chronic) (cryptogenic) (lung) \textit{516.31}
  idiopathic \textit{516.30}
Amentia (see also \textit{Disability, intellectual}) \textit{319}
Anaphylactic \textit{reaction or} shock or reaction (correct substance properly administered) \textit{995.0}
  due to
  administration of blood and blood products \textit{999.41}
  chemical - see Table of Drugs and Chemicals
  correct medicinal substance properly administered \textit{995.0}
  drug or medicinal substance
    correct substance properly administered \textit{995.0}
    overdose or wrong substance given or taken \textit{977.9}
    specified drug - see Table of Drugs and Chemicals
  following sting(s) \textit{989.5}
  immunization \textit{999.42}
  serum NEC \textit{999.49}
  serum NEC \textit{999.49}
Anaphylactoid \textit{reaction or} shock or reaction - see Anaphylactic shock
Anaphylaxis - see Anaphylactic \textit{reaction or} shock
Anaplasmosis, human \textit{082.49}
Anastomosis
  intestinal 569.89
  complicated NEC \textit{997.49}
Anemia \textit{285.9}
  chronic simple \textit{281.9}
  chronic \textit{285.9}
    blood loss \textit{280.0}
    hemolytic \textit{282.9}
      idiopathic \textit{283.9}
      \textit{simple} \textit{281.9}
Cooley's (erythroblastic) \textit{282.44}
  erythroblastic
    familial \textit{282.44}
  familial erythroblastic (microcytic) \textit{282.44}
  high A_2 \textit{282.46}
  leptocytosis (hereditary) \textit{282.40}
Anemia (cont)
Mediterranean (with hemoglobinopathy) 282.40
    with hemoglobinopathy 282.49
microdrenapnoctosis 282.41
Rietti-Greggi-Micheli (thalassemia minor) 282.46
    target cell (oval) 285.8
        with thalassemia - see Thalassemia
thalassemia 282.40

Aneurysm (anastomotic) (artery) (circoid) (diffuse) (false) (fusiform) (multiple) (ruptured) (saccular) (varicose) 442.9
    arteriovenous (congenital) (peripheral) NEC (see also Anomaly, arteriovenous) 747.60
        pulmonary 747.32
    berry (congenital) (ruptured) (see also Hemorrhage, subarachnoid) 430
        nonruptured 437.3
    brain 437.3
        berry (congenital) (ruptured) (see also Hemorrhage, subarachnoid) 430
            nonruptured 437.3
    congenital (peripheral) NEC 747.60
        pulmonary 747.32
        pulmonary 417.1
            arteriovenous 747.32

Anomaly, anomalous (congenital) (unspecified type) 759.9
    artery (see also Anomaly, peripheral vascular system) NEC 747.60
        pulmonary 747.39
    origin
        pulmonary artery 747.39
        artery 747.39
            circulation 747.39
    specified type NEC
        artery (peripheral) NEC (see also Anomaly, peripheral vascular system) 747.60
            pulmonary 747.39

Antibody deficiency syndrome
    agammaglobulinemic 279.00
    anticardiolipin 795.79
        with
            hemorrhagic disorder 286.53
                hypercoagulable state 289.81
            antiphosphatidylglycerol 795.79
                with
                    hemorrhagic disorder 286.53
                        hypercoagulable state 289.81
            antiphosphatidylinositol 795.79
                with
                    hemorrhagic disorder 286.53
                        hypercoagulable state 289.81
            antiphosphatidylserine 795.79
                with
                    hemorrhagic disorder 286.53
                        hypercoagulable state 289.81
            antiphospholipid 795.79
                with
                    hemorrhagic disorder 286.53
                        hypercoagulable state 289.81

deficiency syndrome
    agammaglobulinemic 279.00
    congenital 279.04
Antibody (cont)
deficiency syndrome (cont)
  hypogammaglobulinemic 279.00
  congenital 279.04
  hypogammaglobulinemic 279.00
Anticoagulant, intrinsic, circulating, causing hemorrhagic disorder (see also Circulating anticoagulants) 286.5
intrinsic, circulating, causing hemorrhagic disorder (see also Circulating, anticoagulants) 286.59
  lupus (LAC) 795.79
  with hemorrhagic disorder 286.53
  hypercoagulable state 289.81
Antithrombinemia (see also Circulating anticoagulants) 286.59
Antithromboplastinemia (see also Circulating anticoagulants) 286.59
Antithromboplastinogenemia (see also Circulating anticoagulants) 286.59
Aplasia - see also Agenesis
  red cell (with thymoma) (adult) 284.81
    acquired (secondary) 284.81
      due to drugs 284.81
    adult 284.81
      pure 284.01
      due to drugs 284.81
coronary (artery) 414.00
  due to lipid rich plaque 414.3
  calcified coronary lesion (severely) 414.4
  lipid rich plaque 414.3
Arthritis, arthritic (acute) (chronic) (subacute) 716.9
  due to or associated with serum sickness 999.59 [713.6]
  reactive 099.3
  serum (nontherapeutic) (therapeutic) 999.59 [713.6]
  thalassemia (see also Thalassemia) 282.40 [713.2]
Arthus phenomenon 995.21
due to serum 999.59
Atresia, atretic (congenital) 759.89
  artery NEC (see also Atresia, blood vessel) 747.60
    pulmonary 747.31
  blood vessel (peripheral) NEC 747.60
    pulmonary artery 747.31
    pulmonary (artery) 747.31
Atrophy, atrophic
  bladder 596.89
Autoimmune
  inhibitors to clotting factors 286.52
Automatism 348.89
  with temporal sclerosis 348.81
Aversion
  oral 783.3
    newborn 779.31
    nonorganic origin 307.59
Bacillus - see also Infection, bacillus
  coli
    infection 041.49
Beta thalassemia (major) (minor) (mixed) 282.44
  major 282.44
Beta thalassemia (cont)

minor 282.46

Biemond's syndrome (obesity, polydactyly, and **intellectual disabilities**) 759.89

Blighted ovum **631.8**

Block

alveolar capillary **516.8**

Blood

mole **631.8**

pressure:

high (see also Hypertension) 401.9

**borderline 796.2**

Borderline

**diabetes mellitus 790.29**

**hypertension 796.2**

Brachman-de Lange syndrome (Amsterdam dwarf, **intellectual disabilities**, and brachycephaly) 759.89

Brain - see also condition

dead **348.82**

syndrome (acute) (chronic) (nonpsychotic) (organic) (with neurotic reaction) (with behavioral reaction)

(see also Syndrome, brain) 310.9

congenital (see also **Disability, intellectual**) 319

Breus' mole **631.8**

Bruck-de Lange disease or syndrome (Amsterdam dwarf, **intellectual disabilities**, and brachycephaly) 759.89

Calcification

bladder **596.89**

Carcinoma (M8010/3) - see also Neoplasm, by site, malignant

apocrine (M8401/3)

unspecified site **173.99**

basal cell (pigmented) (M8090/3) *(see also Neoplasm, skin, malignant) 173.91*

ceruminous (M8420/3) **173.29**

squamous (cell) (M8070/3)

**skin (see also Neoplasm, skin, malignant) 173.92**

Cardiomyopathy (congestive) (constrictive) (familial) (infiltrative) (obstructive) (restrictive) (sporadic) 425.4

hypertrophic **425.18**

nonobstructive **425.18**

obstructive **425.11**

Care (of)

prenatal V22.1

high-risk pregnancy V23.9

inconclusive fetal viability **V23.87**

Carneous mole **631.8**

Cementoma (M9273/0) 213.1

gigantiform *(M9275/0)* 213.1

Cesarean delivery, operation or section NEC 669.7

(planned) occurring after 37 completed weeks of gestation but before 39 completed weeks
gestation due to (spontaneous) onset of labor 649.8

Checkup

pregnancy (normal) V22.1

high-risk pregnancy V23.9

inconclusive fetal viability **V23.87**

Cicatrix (adherent) (contracted) (painful) (vicious) 709.2

bladder **596.89**

Circulating **anticoagulants, antibodies, or inhibitors causing hemorrhagic disorder (see also **Anticoagulants) 286.59**

extrinsic 287.8

intrinsic, causing hemorrhagic disorder 286.59
Circulating anticoagulants… (cont)
 intrinsic… (cont)
  with
    acquired hemophilia 286.52
    antiphospholipid antibody 286.53
CLABSI (central line-associated bloodstream infection) 999.32
Closure
  primary angle without glaucoma damage 365.06
Coarctation
  pulmonary artery 747.31
Colibacillosis 041.49
Collapse 780.2
  during or resulting from a surgical procedure 998.00
  postoperative (cardiovascular) 998.09
  thorax 512.89
Communication
  abnormal - see also Fistula
  between
    pulmonary artery and pulmonary vein 747.39
pulmonary artery-pulmonary vein 747.39
Complications
  anastomosis (and bypass) - see also Complications, due to (presence of) any device, implant, or graft
    classified to 996.0-996.5 NEC
  intestinal (internal) NEC 997.49
artificial opening
  cystostomy 596.83
    infection 596.81
    mechanical 596.82
      specified complication NEC 596.83
  bariatric surgery 997.4
    gastric band procedure 539.09
    infection 539.01
      specified procedure NEC 539.89
    infection 539.81
  cystostomy 596.83
    infection 596.81
    mechanical 596.82
      specified complication NEC 596.83
  gastrointestinal, postoperative NEC (see also Complications, surgical procedures) 997.49
  genitourinary device, implant or graft NEC 996.76
  erosion of implanted vaginal mesh 629.31
  exposure of implanted vaginal mesh 629.32
infection and inflammation
  due to (presence of) any device, implant or graft classified to 996.0-996.5 NEC 996.60
  catheter NEC 996.69
    central venous 999.31
      bloodstream 999.32
      localized 999.33
  Hickman 999.31
    bloodstream 999.32
    localized 999.33
  peripherally inserted central (PICC) 999.31
    bloodstream 999.32
    localized 999.33
  portacath (port-a-cath) 999.31
    bloodstream 999.32
Complications (cont)
  infection and inflammation (cont)
    due to... (cont)
      catheter NEC (cont)
        portacath (port-a-cath) (cont)
          localized 999.33
        triple lumen 999.31
          bloodstream 999.32
          localized 999.33
        umbilical venous 999.31
          bloodstream 999.32
          localized 999.33
        central venous catheter 999.31
          bloodstream 999.32
          localized 999.33
        Hickman catheter 999.31
          bloodstream 999.32
          localized 999.33
        peripherally inserted central catheter (PICC) 999.31
          bloodstream 999.32
          localized 999.33
        portacath (port-a-cath) 999.31
          bloodstream 999.32
          localized 999.33
        triple lumen catheter 999.31
          bloodstream 999.32
          localized 999.33
        umbilical venous catheter 999.31
          bloodstream 999.32
          localized 999.33
  mechanical
    catheter NEC 996.59
      cystostomy 596.82
    medical care NEC 999.9
      gastrointestinal NEC 997.49
    respiratory 519.9
      distress syndrome, adult, following trauma or-and surgery 518.52
      insufficiency, acute, postoperative 518.92
    stoma, external
      urinary tract 997.5
    stomach banding 539.09
    stomach stapling 539.89
    surgical procedures 998.9
      cystostomy malfunction 596.82
      infection 596.81
      mechanical 596.82
      specified complication NEC 596.83
    gastrointestinal NEC 997.49
      shock (endotoxic)(hypovolemic)(septic) 998.02
      hypovolemic 998.09
    transfusion (blood)(lymphocytes)(plasma) 999.80
      infection 999.39
      acute 999.34
    transplant NEC - see also Complications, due to (presence of) any device, implant, or graft classified to
      996.0-996.5 NEC
    stem cell(s) 996.88
Complications (cont)
transplant NEC… (cont)
stem cell(s) (cont)

from
peripheral blood 996.88
umbilical cord 996.88
vaccination 999.9
anaphylaxis NEC 999.42
protein sickness 999.52
reaction (allergic) 999.52
Herxheimer’s 995.0
serum 999.52
serum intoxication, sickness, rash, or other serum reaction NEC 999.52
shock (allergic) (anaphylactic) 999.49

Compression
thorax 512.89

Condition - see also Disease
respiratory NEC 519.9
due to
smoke inhalation 508.2

Conflagration - see also Burn, by site
asphyxia (by inhalation of smoke, gases, fumes, or vapors) 987.9

Congestion, congestive
bladder 596.89
lung 786.9
idiopathic, acute 518.52

Contact - see also Exposure (suspected)

Contraction, contracture, contracted
bladder 596.89
hourglass bladder 596.89
vesical 596.89

Converter, tuberculosis (test reaction) 795.51

Cooley’s anemia (erythroblastic) 282.44

Coprostasis 560.32

Cornelia de Lange’s syndrome (Amsterdam dwarf, intellectual disabilities, and brachycephaly) 759.89

Cyst (mucus) (retention) (serous) (simple)
bladder (multiple) (trigone) 596.89
pilar 704.41
pilonidal (infected) (rectum) 685.1
malignant (M9084/3) 173.59
trichilemmal (proliferating) 704.42
vesical (orifice) 596.89

Cystocele
male 596.89

Cystoptosis 596.89

Cystorrhagia 596.89

Cystostomy status V44.50
with complication 596.83
infection 596.81
mechanical 596.82
specified complication NEC 596.83

Cystourethrocele (see also Cystocele)
male 596.89

Dead
ovum, retained 631.8
Death
brain 348.82
Decrease, decreased
blood
pressure 796.3
due to shock following
operation 998.00
Defect, defective 759.9
mental (see also Disability, intellectual) 319
Deficiency, deficient
mental (familial) (hereditary) (see also Disability, intellectual) 319
Deforrmity 738.9
bladder (neck) (sphincter) (trigone) (acquired) 596.89
vesicourethral orifice (acquired) 596.89
Degeneration, degenerative
corticobasal 331.6
de Lange's syndrome (Amsterdam dwarf, intellectual disabilities, and brachycephaly) 759.89
Delivery
cesarean (for) 669.7
(planned) occurring after 37 completed weeks of gestation but before 39 completed weeks
gestation due to (spontaneous) onset of labor 649.8
complicated (by) NEC 669.9
labor, premature (before 37 completed weeks gestation) 644.2
onset (spontaneous) after 37 completed weeks of gestation but before 39 completed
weeks gestation with delivery by (planned) cesarean section 649.8
premature (before 37 completed weeks gestation) 644.2
Dementia 294.20
with behavioral disturbance (aggressive) (combative) (violent) 294.21
congenital (see also Disability, intellectual) 319
due to or associated with condition(s) classified elsewhere
Parkinson's disease
with behavioral disturbance 332.0 [294.11]
without behavioral disturbance 332.0 [294.10]
Dense
breast(s) 793.82
Development
tardy, mental (see also Disability, intellectual) 319
Diabetes, diabetic (brittle) (congenital) (familial) (mellitus) (severe) (slight) (without complication) 250.0
borderline 790.29
Dilatation
bile duct (common) (cystic) (congenital) 751.69
bladder (sphincter) 596.89
pulmonary
artery (idiopathic) 417.8
congenital 747.39
vesical orifice 596.89
Disability, disabilities
intellectual 319
borderline V62.89
mild, IQ 50-70 317
moderate, IQ 35-49 318.0
profound, IQ under 20 318.2
severe, IQ 20-34 318.1
Disease, diseased - see also Syndrome
bladder 596.9
specified NEC 596.89
Disease, diseased... (cont)
Bruck-de Lange (Amsterdam dwarf, *intellectual disabilities*, and brachycephaly) 759.89
Cooley's (erythroblastic anemia) 282.44
Fourier's 608.83
female 616.89
hemoglobin (Hb) 282.7
Bart's 282.43
E (Hb-E) 282.7
thalassemia 282.47
H (Hb-H) 282.43
high fetal gene or hemoglobin thalassemia (*see also Thalassemia*) 282.40
iron
metabolism (see also Hemochromatosis) 275.09
lung NEC 518.89
interstitial (chronic) 515
respiratory bronchiolitis 516.34
of childhood, specified NEC 516.69
lymphoproliferative (chronic) (M9970/1) 238.79
X linked 759.89
Mediterranean (*with hemoglobinopathy*) 282.40
*with hemoglobinopathy* 282.49
microdrenepanocytic 282.41
microvillus *inclusion* (MVD) 751.5
atrophy 751.5
inclusion (MVD) 751.5
Paget's (osteitis deformans) 731.0
extramammary (M8542/3) - see also Neoplasm, skin, malignant
anus 154.3
skin 173.59
polyethylene 996.45
respiratory (tract) 519.9
smoke inhalation 508.2
serum NEC 999.59
Sweeley-Klionsky 272.7
urinary (tract) 599.9
bladder 596.9
specified NEC 596.89
Woillez's (acute idiopathic pulmonary congestion) 518.52
Disorder - see also Disease
alcohol, alcoholic (see also Alcohol) 291.9
induced mood 291.89
bladder 596.9
specified NEC 596.89
hemorrhagic NEC 287.9
due to intrinsic circulating anticoagulants, *antibodies, or inhibitors* 286.59
with
acquired hemophilia 286.52
antiphospholipid antibody 286.53
involuntary emotional expression (IEED) 310.81
mental (nonpsychotic) 300.9
specific, following organic brain damage 310.9
specified type NEC 310.89
mood (see also Disorder, bipolar) 296.90
alcohol-induced 291.89
Disorder ... (cont)
respiration, respiratory NEC 519.9
due to
  smoke inhalation 508.2
Displacement, displaced
  bladder (acquired) 596.89
Disruption
gastrointestinal anastomosis 997.49
Distention
  bladder 596.89
Distortion (congenital)
  artery (peripheral) NEC (see also Distortion, peripheral vascular system) 747.60
  pulmonary 747.39
Distress
  respiratory 786.09
  adult syndrome (following shock, surgery, or trauma and surgery) 518.52
Disturbance - see also Disease
  memory (see also Amnesia) 780.93
  mild, following organic brain damage 310.89
Drainage
  suprapubic, bladder 596.89
Drowned, drowning (near) 994.1
  lung 518.52
Drug - see also condition
  therapy (maintenance) status NEC
    long-term (current) (prophylactic) use V58.69
    bisphosphonates V58.68
    methadone for pain control V58.69
    methadone 304.00
Dyssectasia, vesical neck 596.89
Dysplasia - see also Anomaly
  alveolar capillary, with vein misalignment 516.64
  bladder 596.89
Eaton-Lambert syndrome (see also Syndrome, Lambert-Eaton) 358.30
Effect, adverse NEC
  foodstuffs
    anaphylactic reaction or shock due to food NEC - see Anaphylactic reaction or shock, due to food 995.60
    serum (prophylactic) (therapeutic) NEC 999.59
Embolism 444.9
  aorta, aortic 444.1
  abdominal 444.09
    saddle 444.01
  bifurcation 444.09
  saddle 444.01
  pulmonary (acute) (artery) (vein) 415.19
    healed or old V12.55
    personal history of V12.55
  saddle (aorta) 444.0
    abdominal aorta 444.01
    pulmonary artery 415.13
Embolism (cont)
vein 453.9
  upper extremity *(acute)* 453.83
    *(acute)* 453.83
    *(deep)* 453.82
    *(superficial)* 453.81
  deep 453.82
  superficial 453.81
Encephalitis (bacterial) (chronic) (hemorrhagic) (idiopathic) (nonepidemic) (spurious) (subacute) 323.9
due to
  human immunodeficiency virus [HIV] disease 042 [323.01]
  infection classified elsewhere 136.9 [323.41]
  other infection classified elsewhere 136.9 [323.41]
Encephaloduroarteriomyosynangiosis (EDAMS) 437.5
Encephalopathy (acute) 348.30
due to
  drugs - (see also Table of Drugs and Chemicals) 349.82
  influenza (virus) (see also Influenza) 487.8
    identified
      *(novel)* 2009 novel H1N1 488.19
    serum (nontherapeutic) (therapeutic) 999.59
  metabolic (see also Delirium) 348.31
    drug induced 349.82
Encounter for - see also Admission for
determination of fetal viability of pregnancy V23.87
  joint prosthesis insertion following prior explantation of joint prosthesis V54.82
Endotoxic shock 785.52
  postoperative 998.02
Eosinophilia 288.3
  with
    angiolymphoid hyperplasia (ALHE) 228.01
Erosion
  implanted vaginal mesh
    in, into
      pelvic floor muscles 629.31
      surrounding organ(s) or tissue 629.31
    vaginal prosthetic materials NEC
      in, into
        pelvic floor muscles 629.31
        surrounding organ(s) or tissue 629.31
Escherichia coli (E. coli) - see Infection, Escherichia coli
Eversion
  bladder 596.89
Examination (general) (routine) (of) (for) V70.9
  prenatal V22.1
    high-risk pregnancy V23.9
      to determine fetal viability V23.87
Exposure (suspected) 994.9
  implanted vaginal mesh
    into vagina 629.32
    through vaginal wall 629.32
  to
    uranium V87.02
    vaginal prosthetic materials NEC
      into vagina 629.32
      through vaginal wall 629.32
Factor

V Leiden mutation 289.81

Failure, failed
circulation, circulatory 799.89
peripheral 785.50
postoperative 998.00
hepatic 572.8
due to a procedure 997.49
respiration, respiratory 518.81
acute 518.81
following trauma and surgery 518.51
acute and chronic 518.84
due to following trauma and surgery 518.53
due to following trauma and surgery 518.51
transplant 996.80
stem cell(s) 996.88
from
peripheral blood 996.88
umbilical cord 996.88

Fibrosis, fibrotic
alveolar (diffuse) 516.31
bladder 596.89
lung (atrophic) (capillary) (chronic) (confluent) (massive) (perialveolar) (peribronchial) 515
diffuse (idiopathic) (interstitial) 516.31
pulmonary (chronic) (see also Fibrosis, lung) 515
alveolar capillary block 516.8
idiopathic 516.31
interstitial
diffuse (idiopathic) 516.31

Findings, (abnormal), without diagnosis (examination) (laboratory test) 796.4
antiphosphatidylglycerol antibody 795.79
antiphosphatidylinositol antibody 795.79
antiphosphatidylserine antibody 795.79
lung field (coin lesion) (shadow) 793.19
coin lesion 793.11
PPD 795.51
radiologic (x-ray) 793.99
lung 793.19
skin test, positive 795.79
tuberculin (without active tuberculosis) 795.51
structure, body (echogram) (thermogram) (ultrasound) (x-ray) NEC 793.99
lung 793.19
lung (coin lesion) (shadow) 793.19

Fistula (sinus) 686.9
arteriovenous (acquired) 447.0
congenital (peripheral) 747.60
pulmonary 747.39
pulmonary (vessels) 417.0
congenital 747.39

cystostomy 596.83
pulmonary 510.0
arteriovenous 417.0
congenital 747.39

Fleshy mole 631.8
Flu - see also Influenza
swine (see also Influenza, novel H1N1) 488.42 - see Influenza, (novel) 2009 H1N1
Food
anaphylactic shock - see Anaphylactic reaction or shock, due to food
Fourrier's disease (idiopathic gangrene) 608.83
female 616.89
Fracture (abduction) (adduction) (avulsion) (compression) (crush) (dislocation) (oblique) (separation) (closed)
   829.0
femur, femoral (closed) 821.00
   neck (closed) 820.8
   stress 733.96
   shaft (lower third) (middle third) (upper third) 821.01
   stress 733.97
march 733.95
   femoral neck 733.96
   pelvis 733.98
   shaft of femur 733.97
pelvis, pelvic (bone(s)) (with visceral injury) (closed) 808.8
   multiple (with disruption of pelvic circle) 808.43
      open 808.53
   multiple
      with
      disruption of pelvic circle 808.43
         open 808.53
      disruption of pelvic ring 808.43
         open 808.53
   without
      disruption of pelvic circle 808.44
         open 808.54
      disruption of pelvic ring 808.44
         open 808.54
stress 733.98
stress 733.95
   femoral neck 733.96
   pelvis 733.98
   shaft of femur 733.97
Glaucoma (capsular) (inflammatory) (noninflammatory) (primary) 365.9
angle closure 365.20
   attack 365.22
   crisis 365.22
   primary 365.20
      chronic 365.23
angle recession  365.65
exfoliation  365.52
inflammatory 365.62
neovascular  365.63
normal tension  365.12
open angle 365.10
with
   abnormal optic disc appearance or asymmetry 365.01
      borderline findings, intraocular pressure 365.04
      high risk 365.05
      intraocular pressure 365.01
      low risk 365.01
      thin central corneal thickness (pachymetry) 365.01
      high risk 365.05
      low risk 365.01
      phacoanaphylactic 365.59
Glaucoma… (cont)

- **phacomorphic**
  - acute 365.22
  - borderline 365.06
- **pigment dispersion** 365.13
- secondary NEC 365.60
  - due to
    - steroids 365.31
    - surgery 365.60

- **stage**
  - advanced 365.73
  - early 365.71
  - end-stage 365.73
  - indeterminate 365.74
  - mild 365.71
  - moderate 365.72
  - severe 365.73
  - unspecified 365.70

- **steroid responders** 365.03
  - induced 365.31
  - responders 365.03

- **suspect** 365.00
  - **primary angle closure** 365.02

- **uveitic** 365.62

Glycogenosis (see also Disease, glycogen storage) 271.0

- **pulmonary interstitial** 516.62

  Hamman-Rich syndrome (diffuse interstitial pulmonary fibrosis) **516.33**

  Hematoma (skin surface intact) (traumatic) - see also Contusion

  - aortic intramural - see Dissection, aorta

Hemochromatosis (acquired) (liver) (myocardium) (secondary) 275.03

  - diabetic **275.03**

Hemoglobin - see also condition

  - H Constant Spring 282.43
  - H disease 282.43

Hemophilia (familial) (hereditary) 286.0

  - acquired **286.52**
  - autoimmune 286.52
  - secondary 286.52

Hemorrhage, hemorrhagic (nontraumatic) 459.0

  - bladder **596.89**
  - disorder 287.9

  - due to intrinsic circulating anticoagulants, **antibodies, or inhibitors** 286.59

    - with
      - acquired hemophilia 286.52
      - antiphospholipid antibody 286.53

    - due to
      - intrinsic circulating anticoagulant, **antibodies, or inhibitors** 286.59

    - with
      - acquired hemophilia 286.52
      - antiphospholipid antibody 286.53

  - mole **631.8**
  - vesical **596.89**

Hernia, hernial (acquired) (recurrent) 553.9

  - bladder (sphincter)
    - male **596.89**
    - cystostomy 596.83
Hernia, hernia... (cont)
  prevesical 596.89
  vesical 596.89
  male 596.89
Herxheimer’s reaction 995.91

High
  A\textsubscript{0} anemia 282.46
  blood pressure (see also Hypertension) 401.9
  borderline 796.2
  risk
  pregnancy V23.9
  inconclusive fetal viability V23.87

Histiocytosis (acute) (chronic) (subacute) 277.89
  adult pulmonary Langerhans cell (PLCH) 516.5

History (personal) of
  anaphylactic reaction or shock V13.81
  anaphylaxis V13.81
  disease (of) V13.9
  specified site NEC V13.89
  disorder (of) V13.9
  endocrine V12.29
  gestational diabetes V12.21
  immunity V12.29
  metabolic V12.29
  obstetric V13.29
  affecting management of current pregnancy V23.49
  ectopic pregnancy V23.42
  specified site NEC V13.89
  embolism (pulmonary) V12.51
  pulmonary V12.55
  endocrine disorder V12.29
  gestational diabetes V12.21

family
  disabilities, intellectual V18.4
  disease or disorder (of)
    eye NEC V19.19
    glaucoma V19.11
  glaucoma V19.11
  eye disorder NEC V19.19
  glaucoma V19.11
  glaucoma V19.11
  intellectual disabilities V18.4
  mental retardation - see History, family, intellectual disabilities
  retardation, mental V18.4
  retinitis pigmentosa V19.19
  gestational diabetes V12.21
  immunity disorder V12.29
  metabolic disorder V12.29
  obstetric disorder V13.29
  affecting management of current pregnancy V23.49
  ectopic pregnancy V23.42
  poor obstetric V13.29
  affecting management of current pregnancy V23.49
  ectopic pregnancy V23.42
  thrombosis V12.51
  pulmonary V12.55
Hourglass contraction, contracture
bladder 596.89

Hydrops 782.3
fetal(is) fetal, fetalis or newborn 778.0
due to isoimmunization 773.3
alpha thalassemia 282.43
isoimmunization 773.3

Hyperheparinemia (see also Circulating, intrinsic anticoagulants) 287.5

Hyperplasia, hyperplastic
angiolymphoid, with eosinophilia (ALHE) 228.01
neuroendocrine cell, of infancy 516.61

Hypertension, hypertensive...........................................................Malignant..... Benign ... Unspecified
borderline .................................................................................... - .................. - ............. 796.2
pulmonary (artery) (secondary) ........................................... - .................. - ............. 416.8
with cor pulmonale (chronic) ........................................... - .................. - ............. 416.8
acute ..................................................................................... - .................. - ............. 415.0

cor pulmonale (chronic) ................................................ - .................. - ............. 416.8
acute ..................................................................................... - .................. - ............. 415.0

right heart ventricular strain/failure........................................... - .................. - ............. 416.8
acute ..................................................................................... - .................. - ............. 415.0

Hypertrophy, hypertrophic
bladder (sphincter) (trigone) 596.89
myocardium (see also Hypertrophy, cardiac) 429.3
idiopathic 425.18
subaortic stenosis (idiopathic) 425.11
vesical 596.89

Hypoplasia, hypoplasis 759.89
angiolymphoid, with eosinophilia (ALHE) 228.01
artery (congenital) (peripheral) 747.60
pulmonary 747.31
arteriovenous 747.32
artery 747.31

Hypovolemia 276.52
surgical shock 998.09

IEED (involuntary emotional expression disorder) 310.81
Ileus (adynamic) (bowel) (colon) (inhibitory) (intestine) (neurogenic) (paralytic) 560.1
following gastrointestinal surgery 997.49
postoperative 997.49

Impaction, impacted
bowel, colon, rectum 560.30
by
   calculus 560.32
   specified type NEC 560.32
   intestine(s) 560.30
   by
   calculus 560.32
   specified type NEC 560.32

Inadequate, inadequacy mental (see also Disability, intellectual) 319
Inappropriate secretion

ACTH 255.0
antidiuretic hormone (ADH) (excessive) 253.6
deficiency 253.5
ectopic hormone NEC 259.3
pituitary (posterior) 253.6
change in quantitative human chorionic gonadotropin (hCG) in early pregnancy 631.0
level of quantitative human chorionic gonadotropin (hCG) for gestational age in early pregnancy 631.0
secretion
ACTH 255.0
antidiuretic hormone (ADH) (excessive) 253.6
deficiency 253.5
ectopic hormone NEC 259.3
pituitary (posterior) 253.6

Increase, increased
anticoagulants (antithrombin) (anti-II) (anti-VIIa) (anti-Xa) (anti-XIa) (prothrombin) (see also Anticoagulants) 286.59
anti-IIa 287.8
anti-Xa 287.8
extrinsic 287.8

Infection, infected, infective (opportunistic) 136.9
with lymphangitis - see Lymphangitis
influenza viruses occurring in pigs or other animals - see Influenza, due to identified, novel influenza A virus
lymphangitis - see Lymphangitis
blood stream - see also Septicemia
central line-associated (CLABSI) 999.32
due to central venous catheter 999.32
central line-associated 999.31
bloodstream 999.32
cystostomy 596.83
due to or resulting from
central venous catheter (see also Complications, due to, catheter, central venous) 999.31
bloodstream 999.32
localized 999.33
injection, inoculation, infusion, transfusion, or vaccination (prophylactic) (therapeutic) 999.39
blood and blood products
acute 999.34
Escherichia coli NEC (E. coli) 041.49
non-Shiga toxin-producing 041.49
Shiga toxin-producing (STEC) 041.43
with
unspecified O group 041.43
non-O157 (with known O group) 041.42
O157 (with confirmation of Shiga toxin when H antigen is unknown, or is not H7) 041.41
O157:H- (nonmotile) with confirmation of Shiga toxin 041.41
O157:H7 with or without confirmation of Shiga toxin-production 041.41
specified NEC 041.42
exit site 999.33
insertion site 999.33
port 999.33
reservoir 999.33
tunnel 999.33
ICD-9-CM Index to Diseases and Injuries Addenda
Effective October 1, 2011 (FY12)

Infiltrate, infiltration
  lung (see also Infiltrate, pulmonary) 793.19
    x-ray finding only 793.19
  pulmonary 793.19
    with
      x-ray finding only 793.19
Influenza, influenzal 487.1
  due to identified
    animal origin influenza virus - see Influenza, due to identified, novel influenza A virus
      (novel) 2009 novel H1N1 influenza virus 488.12
    novel influenza A virus 488.82
      with
        encephalopathy 488.89
        involvement of gastrointestinal tract 488.89
        laryngitis 488.82
        manifestations NEC 488.89
        respiratory (acute) (upper) 488.82
        pharyngitis 488.82
        pneumonia 488.81
      novel A/H1N1 (see also Influenza, (novel) 2009 novel H1N1) 488.12
    novel influenza A viruses not previously found in humans - see Influenza, due to identified, novel influenza A virus

Inhalation
  smoke 508.2

Inhibitor, systemic lupus erythematosus (presence of) 286.5
  autoimmune, to clotting factors 286.52
  systemic lupus erythematosus (presence of) 795.79
    with
      hemorrhagic disorder 286.53
      hypercoagulable state 289.81

Injury 959.9
  internal 869.0
    lung 861.20
      aspiration 507.0

Insufficiency, insufficient
  lung (acute) (see also Insufficiency, pulmonary) 518.82
    following trauma and surgery, or shock 518.52
  mental (congenital) (see also Disability, intellectual) 319
    pulmonary (acute) 518.82
      following
        shock 518.52
        surgery 518.52
        trauma 518.52
    respiratory 786.09
    acute 518.82
      following shock, trauma and surgery, or trauma 518.52

Interrogation
  cardiac defibrillator (automatic) (implantable) V53.32
  cardiac pacemaker V53.31
  cardiac (event) (loop) recorder V53.39
  infusion pump (implanted) (intrathecal) V53.09
  neurostimulator V53.02

Intoxication
  serum (prophylactic) (therapeutic) 999.59
ICD-9-CM Index to Diseases and Injuries Addenda
Effective October 1, 2011 (FY12)

Intrauterine contraceptive device
  reinsertion V25.13
  and reinsertion V25.13
  removal V25.12
  and reinsertion V25.13

Inversion
  bladder 596.89

IRIS (Immune Reconstitution Inflammatory Syndrome) 995.90

Irritability 799.22
  bladder 596.89

Irritation
  bladder 596.89

Lack of
  memory (see also Amnesia) 780.93
    mild, following organic brain damage 310.89

Laurence-Moon-Biedl syndrome (obesity, polydactyly, and intellectual disabilities) 759.89

Leakage
  bile from drainage tube (T tube) 997.49

Lepore hemoglobin syndrome 282.45

Leptocytosis, hereditary 282.40

Lesion(s)
  coin, lung 793.11
    lung 518.89
    coin 793.11

Leukoencephalopathy (see also Encephalitis) 323.9

Leukoplakia 702.8

Lipodermatosclerosis 729.39

Long-term (current) (prophylactic) drug use V58.69
  bisphosphonates V58.68
    methadone for pain control V58.69

Loss
  memory (see also Amnesia) 780.93
    mild, following organic brain damage 310.89

Lupus 710.0
  anticoagulant 795.79
    with
      hemorrhagic disorder 286.53
      hypercoagulable state 289.81
      erythematous (discoid) (local) 695.4
      systemic 710.0
      inhibitor (presence of) 795.79
        with hypercoagulable state 289.81

Lymphangioleiomyomatosis 516.4

Lymphangiomyomatosis (M9174/1) – see Neoplasm, connective tissue, uncertain behavior 516.4

Lymphoma (malignant) (M9590/3) 202.8
  small cell and large cell, mixed (diffuse) (M9613/3) 200.8
    nodular (M9691/3) 202.0

Maintenance
  methadone 304.00

Malacoplakia
  bladder 596.89
Malformation (congenital) - see also Anomaly
  arteriovenous
  pulmonary 747.32
Malfunction - see also Dysfunction
cystostomy 596.82
infection 596.81
mechanical 596.82
  specified complication NEC 596.83
Malposition
congenital
  artery (Peripheral) NEC (see also Malposition, congenital, peripheral vascular system) 747.60
  pulmonary 747.39
Mast cell
sarcoma (M9740/3) 202.6
Mediterranean
anemia (with other hemoglobinopathy) 282.40
  with other hemoglobinopathy 282.49
disease or syndrome (hemopathic) 282.40
  with other hemoglobinopathy 282.49
Melanocytosis, neurocutaneous 757.33
Memory disturbance, loss or lack (see also Amnesia) 780.93
  mild, following organic brain damage 310.89
Mendelson's syndrome (resulting from a procedure) 997.32
Mental - see also condition
deficiency (see also Disability, intellectual) 319
insufficiency (congenital) (see also Disability, intellectual) 319
  retardation (see also Retardation, mental) 319 - see Disability, intellectual
subnormality (see also Disability, intellectual) 319
Metaplasia
  squamous cell
  bladder 596.89
Metastasis, metastatic
  mesentery, of neuroendocrine tumor 209.74
Micheli-Rietti syndrome (thalassemia minor) 282.46
Microdrepanocytosis (thalassemia-Hb-S disease) 282.41
  with sickle cell crisis 282.42
Migraine (idiopathic) 346.9

---

Note The following fifth digit subclassification is for use with category 346:

<table>
<thead>
<tr>
<th>Digit</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>without mention of intractable migraine without mention of status migrainosus</td>
</tr>
<tr>
<td></td>
<td>without mention of refractory migraine without mention of status migrainosus</td>
</tr>
<tr>
<td>1</td>
<td>with intractable migraine, so stated, without mention of status migrainosus</td>
</tr>
<tr>
<td></td>
<td>with refractory migraine, so stated, without mention of status migrainosus</td>
</tr>
<tr>
<td>2</td>
<td>without mention of intractable migraine with status migrainosus</td>
</tr>
<tr>
<td></td>
<td>without mention of refractory migraine with status migrainosus</td>
</tr>
<tr>
<td>3</td>
<td>with intractable migraine, so stated, with status migrainosus</td>
</tr>
<tr>
<td></td>
<td>with refractory migraine, so stated, with status migrainosus</td>
</tr>
</tbody>
</table>

complicated 346.0

Molar pregnancy 631.8
Mole (pigmented) (M8720/0) - see also Neoplasm, skin, benign
  blood 631.8
  Breus' 631.8
  carneous 631.8
  fleshy 631.8
  hemorrhagic 631.8
  malignant
  meaning
  malignant hydatidiform mole (M9100/1) 236.1
  pregnancy NEC 631.8
  stone 631.8
Mutation(s)
  factor V Leiden 289.81
  surfactant, of lung 516.63
MVID (microvillus inclusion disease) 751.5
Myelitis (ascending) (cerebellar) (childhood) (chronic) (descending) (diffuse) (disseminated) (pressure)
  (progressive) (spinal cord) (subacute) (see also Encephalitis) 323.9
  due to
  other infection classified elsewhere 136.9 [323.42]
Myocardiopathy (congestive) (constrictive) (familial) (hypertrophic nonobstructive) (idiopathic) (infiltrative)
  (obstructive) (primary) (restrictive) (sporadic) 425.4
  hypertrophic obstructive 425.18
  nonobstructive 425.18
  obstructive 425.11
Necrosis, necrotic
  bladder (aseptic) (sphincter) 596.89
  vesical (aseptic) (bladder) 596.89
ICD-9-CM Index to Diseases and Injuries Addenda
Effective October 1, 2011 (FY12)

<table>
<thead>
<tr>
<th>Neoplasm, neoplastic</th>
<th>Malignant Primary</th>
<th>Malignant Secondary</th>
<th>Malignant Ca in situ</th>
<th>Benign</th>
<th>Uncertain Behavior</th>
<th>Unspecified</th>
</tr>
</thead>
<tbody>
<tr>
<td>abdomen, abdominal</td>
<td>199.1</td>
<td>199.1</td>
<td>234.9</td>
<td>229.9</td>
<td>238.9</td>
<td>239.9</td>
</tr>
<tr>
<td>wall</td>
<td>195.2</td>
<td>198.8</td>
<td>234.8</td>
<td>229.8</td>
<td>238.8</td>
<td>239.8</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.50</td>
<td>192.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.51</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.52</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>ala nasi (external)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>anus, anal</td>
<td>154.3</td>
<td>197.5</td>
<td>230.6</td>
<td>211.4</td>
<td>235.5</td>
<td>239.0</td>
</tr>
<tr>
<td>margin (see also Neoplasm, anus, skin)</td>
<td>173.50</td>
<td>192.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>skin</td>
<td>173.50</td>
<td>192.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.51</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.59</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.52</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>auditory</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>canal (external) (skin)</td>
<td>173.20</td>
<td>192.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>auricle, ear (see also Neoplasm, skin, ear)</td>
<td>173.20</td>
<td>192.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>auricular canal (external) (see also Neoplasm, skin, ear)</td>
<td>173.20</td>
<td>192.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>axilla, axillary</td>
<td>195.1</td>
<td>198.89</td>
<td>234.8</td>
<td>229.8</td>
<td>238.8</td>
<td>239.89</td>
</tr>
<tr>
<td>fold (see also Neoplasm, skin, trunk)</td>
<td>173.50</td>
<td>192.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>breast (connective tissue) (female)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(glandular tissue) (soft parts)</td>
<td>174.9</td>
<td>198.81</td>
<td>230.0</td>
<td>217</td>
<td>238.3</td>
<td>239.3</td>
</tr>
<tr>
<td>mastectomy site (skin)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(see also Neoplasm, mastectomy site)</td>
<td>173.50</td>
<td>192.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>brow (see also Neoplasm, mastectomy site)</td>
<td>173.50</td>
<td>192.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.31</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.39</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.32</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>canal (external) (see also Neoplasm, skin, ear)</td>
<td>173.20</td>
<td>192.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>auricular (external) (see also Neoplasm, skin, ear)</td>
<td>173.20</td>
<td>192.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>canthus (eye) (inner) (outer)</td>
<td>173.10</td>
<td>192.2</td>
<td>232.1</td>
<td>216.1</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.11</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.19</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

Key: Bold – Add; Bold Strikeout – Delete; Bold Underline Italic – Revise
<table>
<thead>
<tr>
<th>Neoplasm, neoplastic (cont)</th>
<th>Malignant Primary</th>
<th>Malignant Secondary</th>
<th>Malignant Ca in situ</th>
<th>Benign</th>
<th>Uncertain Behavior</th>
<th>Unspecified</th>
</tr>
</thead>
<tbody>
<tr>
<td>cheek</td>
<td>195.0</td>
<td>198.89</td>
<td>234.8</td>
<td>229.8</td>
<td>238.8</td>
<td>239.89</td>
</tr>
<tr>
<td>external</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.31</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.39</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.32</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>chin</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.31</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.39</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.32</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>columna (see also Neoplasm, skin, face)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>concha (see also Neoplasm, skin, ear)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>connective tissue NEC</td>
<td>173.390</td>
<td>198.2</td>
<td>232.9</td>
<td>216.9</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>skin (dermis) NEC</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>ear (external) (see also Neoplasm, ear, skin)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>auricle or auris (see also Neoplasm, ear, skin)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>canal, external (see also Neoplasm, ear, skin)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>external meatus (see also Neoplasm, ear, skin)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>lobule (see also Neoplasm, ear, skin)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>skin</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.21</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.29</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.22</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>earlobe</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.21</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.29</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.22</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>external meatus (see also Neoplasm, skin, ear)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>eyebrow</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.31</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.39</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.32</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Neoplasm, neoplastic (cont)</td>
<td>Malignant Primary</td>
<td>Malignant Secondary</td>
<td>Malignant Ca in situ</td>
<td>Benign</td>
<td>Uncertain Behavior</td>
<td>Unspecified</td>
</tr>
<tr>
<td>----------------------------</td>
<td>------------------</td>
<td>--------------------</td>
<td>---------------------</td>
<td>--------</td>
<td>-------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>eyelid (lower) (skin) (upper)</td>
<td>173.10</td>
<td>198.2</td>
<td>232.1</td>
<td>216.1</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.11</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.19</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.12</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>meatus</td>
<td></td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>external (ear)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>skin (see also Neoplasm, skin, ear)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>lid (lower) (upper)</td>
<td>173.10</td>
<td>198.2</td>
<td>232.1</td>
<td>216.1</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.11</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.19</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.12</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>lip (external) (lipstick area) (vermilion border)</td>
<td>140.9</td>
<td>198.89</td>
<td>232.0</td>
<td>216.0</td>
<td>238.2</td>
<td>239.0</td>
</tr>
<tr>
<td>skin (commissure) (lower) (upper)</td>
<td>173.00</td>
<td>198.2</td>
<td>232.0</td>
<td>216.0</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.01</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.09</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.02</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>mastectomy site (skin)</td>
<td>173.50</td>
<td>198.2</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.51</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.59</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.52</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>meatus</td>
<td></td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>external (ear) (see also Neoplasm, skin, ear)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>meibomian gland</td>
<td>173.10</td>
<td>198.2</td>
<td>232.1</td>
<td>216.1</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.11</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.19</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.12</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>nail</td>
<td></td>
<td>198.2</td>
<td>232.9</td>
<td>216.9</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>finger (see also Neoplasm, skin, limb, upper)</td>
<td>173.60</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>toe (see also Neoplasm, skin, limb, lower)</td>
<td>173.70</td>
<td>198.2</td>
<td>232.7</td>
<td>216.7</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>nasolabial groove (see also Neoplasm, skin, face)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>nates (see also Neoplasm, skin, trunk)</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
</tbody>
</table>

Key: Bold – Add; Bold Strikeout – Delete; Bold Underline Italic – Revise
<table>
<thead>
<tr>
<th>Neoplasm, neoplastic (cont)</th>
<th>Malignant Primary</th>
<th>Malignant Secondary</th>
<th>Malignant Ca in situ</th>
<th>Benign</th>
<th>Uncertain Behavior</th>
<th>Unspecified</th>
</tr>
</thead>
<tbody>
<tr>
<td>neck NEC*</td>
<td>195.0</td>
<td>198.89</td>
<td>234.8</td>
<td>229.8</td>
<td>238.8</td>
<td>239.89</td>
</tr>
<tr>
<td>skin</td>
<td>173.40</td>
<td>198.2</td>
<td>232.4</td>
<td>216.4</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.41</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.49</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.42</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>nose, nasal</td>
<td>195.0</td>
<td>198.89</td>
<td>234.8</td>
<td>229.8</td>
<td>238.8</td>
<td>239.89</td>
</tr>
<tr>
<td>ala (external) (see also Neoplasm, nose, skin)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>external (skin) (see also Neoplasm, nose, skin)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>skin</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.31</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.39</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.32</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>palpebra</td>
<td>173.10</td>
<td>198.2</td>
<td>232.1</td>
<td>216.1</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.11</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.19</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.12</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>perianal (skin) (see also Neoplasm, skin, anus)</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>pinna (ear) NEC (see also Neoplasm, skin, ear)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>scalp</td>
<td>173.40</td>
<td>198.2</td>
<td>232.4</td>
<td>216.4</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.41</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.49</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.42</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>scar NEC (see also Neoplasm, skin)</td>
<td>173.90</td>
<td>198.2</td>
<td>232.9</td>
<td>216.9</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>skin NEC NOS</td>
<td>173.90</td>
<td>198.2</td>
<td>232.9</td>
<td>216.9</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>abdominal wall</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.51</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.59</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.52</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>ala nasi (see also Neoplasm, skin, face)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>ankle (see also Neoplasm, skin, limb, lower)</td>
<td>173.70</td>
<td>198.2</td>
<td>232.7</td>
<td>216.7</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>antecubital space (see also Neoplasm, skin, limb, lower)</td>
<td>173.60</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>(see also Neoplasm, skin, limb, upper)</td>
<td>173.60</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.51</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.59</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.52</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>ankle (see also Neoplasm, skin, limb, upper)</td>
<td>173.60</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td><strong>Neoplasm, neoplastic (cont)</strong></td>
<td><strong>Malignant</strong></td>
<td><strong>Malignant</strong></td>
<td><strong>Malignant</strong></td>
<td><strong>Benign</strong></td>
<td><strong>Uncertain</strong></td>
<td><strong>Unspecified</strong></td>
</tr>
<tr>
<td>---------------------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
<td>-----------</td>
<td>--------------</td>
<td>----------------</td>
</tr>
<tr>
<td>skin (cont)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>auditory canal (external) (see also Neoplasm, skin, ear)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>auricle (ear) (see also Neoplasm, skin, ear)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>auricular canal (external) (see also Neoplasm, skin, ear)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>axilla, axillary fold (see also Neoplasm, skin, trunk)</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>back</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.51</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.59</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.52</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>basal cell carcinoma, unspecified site</td>
<td>173.91</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>breast (see also Neoplasm, skin, trunk)</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>brow (see also Neoplasm, skin, face)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>buttock (see also Neoplasm, skin, trunk)</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>calf (see also Neoplasm, skin, limb, lower)</td>
<td>173.70</td>
<td>198.2</td>
<td>232.7</td>
<td>216.7</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>canthus (eye) (inner) (outer)</td>
<td>173.10</td>
<td>198.2</td>
<td>232.1</td>
<td>216.1</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.11</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.19</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.12</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>cervical region (see also Neoplasm, skin, neck)</td>
<td>173.40</td>
<td>198.2</td>
<td>232.4</td>
<td>216.4</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>cheek (external) (see also Neoplasm, skin, face)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>chest (wall) (see also Neoplasm, skin, trunk)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>chin (see also Neoplasm, skin, trunk)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>clavicular area (see also Neoplasm, skin, trunk)</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>columnella (see also Neoplasm, skin, face)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>concha (see also Neoplasm, skin, ear)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>contiguous sites</td>
<td>173.80</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.81</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.89</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.82</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>ear (external)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.21</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.29</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.22</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>elbow (see also Neoplasm, skin, limb, upper)</td>
<td>173.60</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>eyebrow (see also Neoplasm, skin, face)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>Neoplasm, neoplastic (cont)</td>
<td>Malignant Primary</td>
<td>Malignant Secondary</td>
<td>Malignant Ca in situ</td>
<td>Benign</td>
<td>Uncertain Behavior</td>
<td>Unspecified</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------</td>
<td>-------------------</td>
<td>---------------------</td>
<td>-------</td>
<td>-------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>skin (cont)</td>
<td>173.10</td>
<td>198.2</td>
<td>232.1</td>
<td>216.1</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>eyelid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>face NEC</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.31</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.39</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.32</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>finger (see also Neoplasm, skin, limb, upper)</td>
<td>173.60</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>flank (see also Neoplasm, skin, trunk)</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>foot (see also Neoplasm, skin, limb, lower)</td>
<td>173.70</td>
<td>198.2</td>
<td>232.7</td>
<td>216.7</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>forearm (see also Neoplasm, skin, limb, upper)</td>
<td>173.60</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>forehead (see also Neoplasm, skin, face)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>glabella (see also Neoplasm, skin, face)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>gluteal region (see also Neoplasm, skin, trunk)</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>groin (see also Neoplasm, skin, trunk)</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>hand (see also Neoplasm, skin, limb, upper)</td>
<td>173.60</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>head NEC (see also Neoplasm, skin, scalp)</td>
<td>173.40</td>
<td>198.2</td>
<td>232.4</td>
<td>216.4</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>heel (see also Neoplasm, skin, limb, lower)</td>
<td>173.70</td>
<td>198.2</td>
<td>232.7</td>
<td>216.7</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>helix (see also Neoplasm, skin, ear)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>hip</td>
<td>173.70</td>
<td>198.2</td>
<td>232.7</td>
<td>216.7</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.71</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.79</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.72</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>infraclavicular region (see also Neoplasm, skin, trunk)</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>inguinal region (see also Neoplasm, skin, trunk)</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>jaw (see also Neoplasm, skin, face)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>knee (see also Neoplasm, skin, limb, lower)</td>
<td>173.70</td>
<td>198.2</td>
<td>232.7</td>
<td>216.7</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>leg (see also Neoplasm, skin, limb, lower)</td>
<td>173.70</td>
<td>198.2</td>
<td>232.7</td>
<td>216.7</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>lid (lower) (upper)</td>
<td>173.10</td>
<td>198.2</td>
<td>232.1</td>
<td>216.1</td>
<td>238.2</td>
<td>239.2</td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Key: Bold – Add; Bold Strikeout – Delete; Bold Underline Italic – Revise
### Neoplasm, neoplastic (cont)

#### skin (cont)

<table>
<thead>
<tr>
<th>Location</th>
<th>Code</th>
<th>Malignant Primary</th>
<th>Malignant Secondary</th>
<th>Malignant Ca in situ</th>
<th>Benign</th>
<th>Uncertain Behavior</th>
<th>Unspecified</th>
</tr>
</thead>
<tbody>
<tr>
<td>limb NEC</td>
<td>173.90</td>
<td>198.2</td>
<td>232.9</td>
<td>216.9</td>
<td>238.2</td>
<td>239.5</td>
<td></td>
</tr>
<tr>
<td>lower</td>
<td>173.70</td>
<td>198.2</td>
<td>232.7</td>
<td>216.7</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.71</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.79</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.72</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>upper</td>
<td>173.60</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.61</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.69</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.62</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>lip (lower) (upper)</td>
<td>173.00</td>
<td>198.2</td>
<td>232.0</td>
<td>216.0</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.01</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.09</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.02</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>mastectomy site</td>
<td>173.50</td>
<td>198.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>meatus, acoustic (external)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>nates</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>neck</td>
<td>173.40</td>
<td>198.2</td>
<td>232.4</td>
<td>216.4</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.41</td>
<td>198.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.49</td>
<td>198.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.42</td>
<td>198.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>nose (external)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>palm</td>
<td>173.60</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>palpebra</td>
<td>173.10</td>
<td>198.2</td>
<td>232.1</td>
<td>216.1</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.11</td>
<td>198.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.19</td>
<td>198.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.12</td>
<td>198.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>perianal</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>perineum</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>pinna</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>plantar</td>
<td>173.70</td>
<td>198.2</td>
<td>232.7</td>
<td>216.7</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>poplitreal fossa or space</td>
<td>173.70</td>
<td>198.2</td>
<td>232.7</td>
<td>216.7</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>pubes</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>sacrococcygeal region</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>Neoplasm, neoplastic (cont)</td>
<td>Malignant Primary</td>
<td>Malignant Secondary</td>
<td>Malignant Ca in situ</td>
<td>Benign</td>
<td>Uncertain Behavior</td>
<td>Unspecified</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------</td>
<td>--------------------</td>
<td>---------------------</td>
<td>-------</td>
<td>-------------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>skin (cont)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>scalp</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.41</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.49</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.42</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>scapular region (see also Neoplasm, skin, trunk)</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>shoulder</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.60</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.69</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.62</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>sole (foot) (see also Neoplasm, skin, limb, lower)</td>
<td>173.70</td>
<td>198.2</td>
<td>232.7</td>
<td>216.7</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>specified sites NEC</td>
<td>173.80</td>
<td>198.2</td>
<td>232.8</td>
<td>216.8</td>
<td>232.8</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.81</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.89</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.82</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>specified type NEC, unspecified site</td>
<td>173.99</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma, unspecified site</td>
<td>173.92</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>submammary fold (see also Neoplasm, skin, trunk)</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>supraclavicular region (see also Neoplasm, skin, neck)</td>
<td>173.40</td>
<td>198.2</td>
<td>232.4</td>
<td>216.4</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>temple (see also Neoplasm, skin, face)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>thigh (see also Neoplasm, skin, face)</td>
<td>173.40</td>
<td>198.2</td>
<td>232.4</td>
<td>216.4</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>thoracic wall (see also Neoplasm, skin, trunk)</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>thumb (see also Neoplasm, skin, limb, lower)</td>
<td>173.60</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>toe (see also Neoplasm, skin, limb, upper)</td>
<td>173.70</td>
<td>198.2</td>
<td>232.7</td>
<td>216.7</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>tragus (see also Neoplasm, skin, ear)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>trunk</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>basal cell carcinoma</td>
<td>173.51</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>specified type NEC</td>
<td>173.59</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>squamous cell carcinoma</td>
<td>173.52</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>umbilicus (see also Neoplasm, skin, trunk)</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>wrist (see also Neoplasm, skin, limb, upper)</td>
<td>173.60</td>
<td>198.2</td>
<td>232.6</td>
<td>216.6</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>sudoriferous, sudoriparous gland, site unspecified</td>
<td>173.90</td>
<td>198.2</td>
<td>232.9</td>
<td>216.9</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>sweat gland (apocrine) (eccrine), site unspecified</td>
<td>173.90</td>
<td>198.2</td>
<td>232.9</td>
<td>216.9</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>temple (skin) (see also Neoplasm, skin, face)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>temporal region</td>
<td>195.0</td>
<td>198.89</td>
<td>234.8</td>
<td>229.8</td>
<td>238.8</td>
<td>239.89</td>
<td></td>
</tr>
<tr>
<td>skin (see also Neoplasm, skin, face)</td>
<td>173.30</td>
<td>198.2</td>
<td>232.3</td>
<td>216.3</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>Neoplasm, neoplastic (cont)</td>
<td>Malignant Primary</td>
<td>Malignant Secondary</td>
<td>Malignant Ca in situ</td>
<td>Benign</td>
<td>Uncertain Behavior</td>
<td>Unspecified</td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------------------</td>
<td>---------------------</td>
<td>--------------------</td>
<td>-------</td>
<td>-------------------</td>
<td>------------</td>
<td></td>
</tr>
<tr>
<td>tragus (see also Neoplasm, skin, ear)</td>
<td>173.20</td>
<td>198.2</td>
<td>232.2</td>
<td>216.2</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
<tr>
<td>umbilicus, umbilical (see also Neoplasm, skin, trunk)</td>
<td>173.50</td>
<td>198.2</td>
<td>232.5</td>
<td>216.5</td>
<td>238.2</td>
<td>239.2</td>
<td></td>
</tr>
</tbody>
</table>
Neuritis (see also Neuralgia) 729.2
  serum 999.59
Nevus (M8720/0) - see also Neoplasm, skin, benign
dermal  (M8750/0)
Nodule(s), nodular
  lung, solitary 518.89
  solitary 793.11
  pulmonary, solitary (subsegmental branch of the bronchial tree) 793.11
    multiple 793.19
Observation (for) V71.9
  pregnancy
    high-risk V23.9
    inconclusive fetal viability V23.87
Obstruction, obstructed, obstructive
  aortoiliac 444.09
  intestine (mechanical) (neurogenic) (paroxysmal) (postinfectious) (reflex) 560.9
    due to
    procedure 997.49
    impaction 560.32
Occlusion
  aortoiliac (chronic) 444.09
Oligergasia (see also Disability, intellectual) 319
Oligophrenia (see also Disability, intellectual) 319
Open, opening
  angle with
    borderline intraocular pressure 365.04
    with
      borderline findings
        high risk 365.05
        intraocular pressure 365.01
        low risk 365.01
      cupping of discs 365.01
    cupping of discs 365.04
    high risk 365.05
    low risk 365.01
Osteomalacia 268.2
  oncogenic 275.8
Ovum
  blighted 631.8
  dropsical 631.8
  pathologic 631.8
Paget’s disease (osteitis deformans) 731.0
  extramammary (M8542/3) - see also Neoplasm, skin, malignant
    anus 154.3
    skin 173.59
Pain(s) (see also Painful) 780.96
  temporomaxillary joint 524.62
Pancytopenia (acquired) 284.19
  with malformations 284.09
  malformations 284.09
  myelodysplastic syndrome - see Syndrome, myelodysplastic
    due to
      antineoplastic chemotherapy 284.11
      drug, specified NEC 284.12
      specified NEC 284.19
PBA (pseudobulbar affect) **310.81**
Placenta, placental
carneous mole **631.8**
fleshy mole **631.8**
Plateau iris syndrome (without glaucoma) 364.82
with glaucoma 365.23
with influenza, flu, or gripe 487.0
due to
identified (virus) **(novel) 2009 novel**H1N1 488.11
novel influenza A 488.81
broncho-, bronchial (confluent) (croupous) (diffuse) (disseminated) (hemorrhagic) (involving lobes) (lobar) (terminal) 485
with influenza 487.0
due to
identified (virus) **(novel) 2009 novel**H1N1 488.11
novel influenza A 488.81
cryptogenic organizing **516.36**
desquamative interstitial 516.37
interstitial 516.8
acute 436.3
due to Pneumocystis (carinii) (jiroveci) 136.3
meaning:
acute interstitial pneumonitis 516.33
atypical pneumonia - see Pneumonia, atypical
bacterial pneumonia - see Pneumonia, bacterial
desquamative **516.37**
idioopathic 516.30
lymphoid 516.35
lymphoid **(due to known underlying cause)** 516.8
non-specific (due to known underlying cause) 516.8
organizing (due to known underlying cause) 516.8
postoperative 997.39
aspiration 997.32
resulting from a procedure 997.39
aspiration 997.32
Pneumonitis (acute) (primary) (see also Pneumonia) 486
chemical 506.0
resulting from a procedure 997.32
interstitial (chronic) (see also Fibrosis, lung) 515
acute 516.33
idiopathic
lymphocytic 516.35
non-specific 516.32
postoperative 997.39
aspiration 997.32
Pneumothorax *(acute) (chronic)* 512.89
  - acute 512.89
  - chronic 512.83
  - specified type NEC 512.89
  - spontaneous 512.89
    - primary 512.81
    - secondary 512.82
  - sucking 512.89

Poor
  - obstetrical history V13.29
    - affecting management of current pregnancy V23.49
      - ectopic pregnancy V23.42

Positive
  - PPD 795.51
  - skin test 795.7
    - tuberculin (without active tuberculosis) 795.51

Postencephalitic - see also condition
  - syndrome 310.89

Pregnancy (single) (uterine) (without sickness) V22.2
  - **biochemical** 631.0
  - **chemical** 631.0
  - complicated (by) 646.9
    - cholestasis 646.7
      - current disease or condition (nonobstetric)
        - **biliary tract** 646.7
      - disorders of liver *and biliary tract* 646.7
      - **insulin resistance** 648.8
        - previous
          - ectopic pregnancy V23.42
          - retention, retained dead ovum 631.8
    - management affected by
      - **insulin resistance** 648.8
        - previous
          - ectopic pregnancy V23.42
    - molar 631.8
    - observation NEC V22.1
      - high-risk V23.9
        - inconclusive fetal viability V23.87
    - prenatal care only V22.1
      - high-risk V23.9
        - inconclusive fetal viability V23.87
    - supervision (of) (for) - see also Pregnancy, management affected by
      - high-risk V23.9
        - inconclusive fetal viability V23.87
        - inconclusive fetal viability V23.87
        - poor
          - obstetric history V23.49
          - ectopic pregnancy V23.42

Primary - see also condition
  - **angle closure suspect** 365.02

Problem (with) V49.9
  - behavioral V40.9
    - specified NEC V40.39

Prognathism (mandibular) (maxillary) 524.10
Prolapse, prolapsed
  bladder (acquired) (mucosa) (sphincter)
    male 596.89
  cystostomy 596.83
Protein
  sickness (prophylactic) (therapeutic) 999.59
Pseudobulbar affect (PBA) 310.81
Rash 782.1
  serum (prophylactic) (therapeutic) 999.59
Reaction
  allergic (see also Allergy) 995.3
    serum 999.59
  anaphylactic - see also Allergy 999.85
    Shock, anaphylactic - see also Allergy 999.85
    Anaphylactic reaction 999.85
  food - see also Allergy, food
    anaphylactic shock - see Anaphylactic reaction or shock, due to, food
  Herxheimer’s 995.91
    nonspecific
      to cell mediated immunity measurement of gamma interferon antigen response without active tuberculosis 795.52
      QuantiFERON-TB test (QFT) without active tuberculosis 795.52
      tuberculin test (see also Reaction, tuberculin skin test) 795.51
    serum (prophylactic) (therapeutic) 999.59
      anaphylactic 999.49
    due to
      administration of blood and blood products 999.51
        anaphylactic 999.41
        vaccination 999.52
        anaphylactic 999.41
      immediate 999.49
      tuberculin skin test, nonspecific (without active tuberculosis) 795.51
      positive (without active tuberculosis) 795.51
Rejection
  transplant 996.80
    stem cell(s) 996.88
      from
        peripheral blood 996.88
        umbilical cord 996.88
Residual - see also condition
  bladder 596.89
Resistance, resistant (to)
  insulin 277.7
    complicating pregnancy 648.8
Respiration
  failure 518.81
    acute 518.81
      following trauma and surgery 518.51
    acute and chronic 518.84
      following trauma and surgery 518.53
    chronic 518.83
      following trauma and surgery 518.51
Respiratory - see also condition
distress 786.09
   syndrome (newborn) 769
   adult (following shock, surgery, or trauma) and surgery 518.52
failure 518.81
   acute 518.81
   following trauma and surgery 518.51
   acute and chronic 518.84
   following trauma and surgery 518.53
   chronic 518.83
   following trauma and surgery 518.51

Retardation
   mental - see Disability, intellectual 314.9
      borderline V62.89
      mild, IQ 50-70 317
      moderate, IQ 35-49 318.0
      profound, IQ under 20 318.2
      severe, IQ 20-34 318.1

Retention, retained
cholelithiasis, following cholecystectomy 997.41
dead
   ovum 631.8
gallstones, following cholecystectomy 997.41
Rietti-Greppi-Micheli anemia or syndrome 282.46
Rubinstein-Taybi’s syndrome (brachydactyly, short stature and intellectual disabilities) 759.89
Rupture, ruptured 553.9
   rotator cuff (capsule) (traumatic) 840.4
   nontraumatic, (complete) 727.61
      partial 726.13
   tendon (traumatic) - see also Sprain, by site
   rotator cuff (capsule) 840.4
   nontraumatic, (complete) 727.61
      partial 726.13

Saddle
   embolus, aorta 444.0
   abdominal aorta 444.01
   pulmonary artery 415.13
   injury - code to condition
Screening (for) V82.9
   intellectual disabilities V79.2
   mental
      retardation - see Screening, intellectual disabilities V79.2
Seizure(s) 780.39
   recurrent 345.8
Sensitivity, sensitization - see also Allergy
tuberculin, without clinical or radiological symptoms 795.51
Sepsis (generalized) 995.91
   intra-abdominal 567.22
   localized - code to specific localized infection
   - see also condition
   shock (endotoxic) 785.52
      postoperative 998.02
Septum, septate (congenital) - see also Anomaly, specified type NEC
   uterus (see also Double, uterus) (complete) (partial) 752.35
Sequestration
   pulmonary artery (congenital) 747.39
Serum
  allergy, allergic reaction **999.59**
  shock **999.49**
arthritis **999.59** [713.6]
complication or reaction NEC **999.59**
disease NEC **999.59**
intoxication **999.59**
neuritis **999.59**
poisoning NEC **999.59**
rash NEC **999.59**
reaction NEC **999.59**
sickness NEC **999.59**
Shadow, lung **793.19**
Shock 785.50
  allergic - see **Shock, anaphylactic Anaphylactic reaction or shock**
  anaphylactic see also **Anaphylactic reaction or shock 995.0**
    chemical - see Table of Drugs and Chemicals
    correct medicinal substance properly administered 995.0
    drug or medicinal substance
      correct substance properly administered 995.0
      overdose or wrong substance given or taken 977.9
      specified drug - see Table of Drugs and Chemicals
due to administration of blood and blood products 999.41
  following sting(s) 989.5
  food - see **Anaphylactic shock, due to, food Immunization 999.4**
  serum 999.4
anaphylactoid - see **Shock, anaphylactic Anaphylactic reaction or shock**
endotoxic 785.52
  due to surgical procedure **998.02**
  postoperative 998.02
gram-negative 785.52
  postoperative 998.02
hemorrhagic
due to
  surgery (intraoperative) (postoperative) **998.09**
hypovolemic NEC 785.59
  surgical **998.09**
lung **518.82**
  related to trauma and surgery 518.52
pleural (surgical) **998.09**
postoperative **998.00**
  cardiogenic 998.01
  hypovolemic 998.09
  specified NEC 998.09
  septic (endotoxic) (gram-negative) 998.02
septic 785.52
due to
  surgical procedure **998.02**
  following
    surgical procedure **998.02**
    postoperative 998.02
surgical **998.00**
Shunt (status)
  arteriovenous, pulmonary (acquired) 417.0
  congenital **747.39**
Sickness
- protein (see also Complications, vaccination) 999.59
  serum NEC 999.59
Siderosis (lung) (occupational) 503
- central nervous system (CNS) 437.8
Sloughing (multiple) (skin) 686.9
  bladder 596.89
Solitary
- ulcer, bladder 596.89
Spasm, spastic, spasticity (see also condition) 781.0
  bladder (sphincter, external or internal) 596.89
  vesical (sphincter, external or internal) 596.89
Squamous - see also condition
- cell metaplasia
  bladder 596.89
  metaplasia
  bladder 596.89
Status (post)
- explantation of joint prosthesis NEC V88.29
  hip V88.21
  knee V88.22
  hip prosthesis (joint) (partial) (total) V43.64
  explantation V88.21
  joint prosthesis NEC V43.69
  explantation V88.29
  knee joint prosthesis V43.65
  explantation V88.22
Stenosis (cicatricial) - see also Stricture
- artery NEC (see also Arteriosclerosis) 447.1
  pulmonary (congenital) 747.31
  hypertrophic subaortic (idiopathic) 425.11
  myocardiun, myocardial (see also Degeneration, myocardial) 429.1
    hypertrophic subaortic (idiopathic) 425.11
    nares (anterior) (posterior) 478.19
    pulmonary (artery) (congenital) 747.31
    subaortic 746.81
    hypertrophic (idiopathic) 425.11
Stent jail 996.72
Stoma malfunction
- cystostomy 596.82
  infection 596.81
  mechanical 596.82
  specified complication NEC 596.83
Stricture (see also Stenosis) 799.89
- artery 447.1
  pulmonary (congenital) 747.31
  bladder 596.89
  cystostomy 596.83
  myocardiun, myocardial (see also Degeneration, myocardial 429.1
    hypertrophic subaortic (idiopathic) 425.11
    pulmonary, pulmonic
      artery (congenital) 747.31
    stoma (following) (of)
      cystostomy 596.83
      subaortic 746.81
    hypertrophic (acquired) (idiopathic) 425.11
Subnormal, subnormality
  mental (see also Disability, intellectual) 319
Suprapubic drainage 596.89
Surgical
  shock 998.00
Syndrome - see also Disease
  alveolar capillary block 516.8
  aortic
    bifurcation (occlusion) 444.09
  Bardet-Biedl (obesity, polydactyly, and intellectual disabilities) 759.89
  Biedl-Bardet (obesity, polydactyly, and intellectual disabilities) 759.89
  Biemond's (obesity, polydactyly, and intellectual disabilities) 759.89
  Brachman-de Lange (Amsterdam dwarf, intellectual disabilities, and brachycephaly) 759.89
  brain (acute) (chronic) (nonpsychotic) (organic) (with behavioral reaction)
    (with neurotic reaction) 310.9
    congenital (see also Disability, intellectual) 319
  Cornelia de Lange's (Amsterdam dwarf, intellectual disabilities, and brachycephaly) 759.8
  de Lange's (Amsterdam dwarf, intellectual disabilities, and brachycephaly) (Cornelia) 759.89
  Eaton-Lambert (see also Syndrome, Lambert-Eaton) 358.30
  Hamman-Rich (diffuse interstitial pulmonary fibrosis) 516.33
  hepatopulmonary 573.5
  hepatorenal 572.4
  due to a procedure 997.49
  immune reconstitution inflammatory (IRIS) 995.90
  Lambert-Eaton 358.30
    in
diseases classified elsewhere 358.39
  neoplastic disease 358.31
Laurence-Moon -(Bardet)-Biedl (obesity, polydactyly, and intellectual disabilities) 759.89
Lepore hemoglobin 282.45
Leriche's (aortic bifurcation occlusion) 444.09
Mendelson's (resulting from a procedure) 997.32
Micheli-Rietti (thalassemia minor) 282.46
myelodysplastic 238.75
  lesions, low grade 238.72
plateau iris (without glaucoma) 364.82
  with glaucoma 365.23
post chemoembolization - code to associated conditions
  postencephalitic 310.89
  psycho-organic 293.9
    nonpsychotic severity 310.1
    specified focal (partial) NEC 310.89
  respiratory distress (idiopathic) (newborn) 769
adult (following shock, surgery, or trauma and surgery) 518.52
  Rietti-Greppi-Micheli (thalassemia minor) 282.46
Rubinstein-Taybi's (brachydactyia, short stature, and intellectual disabilities) 759.89
  shock (traumatic) 958.4
  lung 518.82
    related to trauma and surgery 518.52
Silvestroni-Bianco (thalassemia minima) 282.46
superior
  semi-circular canal dehiscence 386.8
wet
  lung
    adult 518.52
    newborn 770.6
ICD-9-CM Index to Diseases and Injuries Addenda
Effective October 1, 2011 (FY12)

System, systemic - see also condition
  lupus erythematosus 710.0
    inhibitor **795.79**

Target-oval cell anemia **285.8**
  with thalassemia - see Thalassemia

Tear, torn (traumatic) - see also Wound, open, by site
  annular fibrosis 722.51
  rotator cuff (traumatic) 840.4
    nontraumatic (**complete**) 727.61
      partial 726.13

Thalassanemia 282.40
  Thalassemia (**alpha**) (**beta**) (disease) (Hb-C) (Hb-D) (Hb-E) (Hb-H) (Hb-I) (high fetal gene) (high fetal hemoglobin) (intermedia) (major) (minima) (minor) (mixed) (trait) (with other hemoglobinopathy) 282.40
    with other hemoglobinopathy 282.49
  alpha (major) (severe) (triple gene defect) 282.43
    silent carrier 282.46
  beta (homozygous) (major) (severe) 282.44
  delta-beta (homozygous) 282.45
  dominant 282.49

  hemoglobin
    C (Hb-C) 282.49
    D (Hb-D) 282.49
    E (Hb-E) 282.49
    E-beta 282.47
    H (Hb-H) 282.49
    I (Hb-I) 282.49
    high fetal gene (see also Thalassemia) 282.40
    high fetal hemoglobin (see also Thalassemia) 282.40
    intermedia 282.44
    major 282.44
    minor (alpha) (beta) 282.46
    mixed 282.49
    specified NEC 282.49
    trait (alpha) (beta) (delta-beta) 282.46

Thrombosis, thrombotic (marantic) (multiple) (progressive) (vein) (vessel) 453.9
  aorta, aortic 444.1
    abdominal **444.09**
      saddle 444.01
    bifurcation **444.09**
      saddle 444.01
      terminal **444.09**
    artery, arteries (postinfectional) 444.9
    pulmonary 415.19
      personal history of **V12.55**
      iliac (acute) (vein) **453.41**
      chronic **453.51**
    lung 415.19
      personal history of **V12.55**
      pulmonary (artery) (vein) 415.19
      personal history of **V12.55**
ICD-9-CM Index to Diseases and Injuries Addenda
Effective October 1, 2011 (FY12)

Thrombosis... (cont)
  upper extremity *(acute)* 453.83
  **acute** 453.83
    deep 453.82
    superficial 453.84
  deep 453.82
  superficial 453.81

Trabeculation, bladder 596.89
Traction, vitreomacular 379.27

Trait
  hemoglobin
    abnormal NEC 282.7
    with thalassemia 282.46
    thalassemia *(alpha) (beta) (delta-beta)* 282.46

Transplant (ed)
  complication - see also Complications, due to (presence of) any device, implant, or graft classified to
  996.0-996.5 NEC
  stem cell(s) 996.88
    from
      peripheral blood 996.88
      umbilical cord 996.88

Tuberculosis, tubercular, tuberculous (calcification) (calcified) (caseous) (chromogenic acid-fast bacilli)
  (congenital) (degeneration) (disease) (fibrocaseous) (fistula) (gangrene) (interstitial) (isolated
  circumscribed lesions) (necrosis) (parenchymatous) ( ulcerative) 011.9
  converter *(tuberculin skin test) (without disease)* 795.51
  latent 795.51

Ulcer, ulcerated, ulcerating, ulceration, ulcerative 707.9
  bladder *(solitary) (sphincter)* 596.89
  vesical (see also Ulcer, bladder) 596.89

Urinoma NEC 599.9
  bladder 596.89

Urticaria 708.9
  due to
    serum 999.59
    *serum 999.59*

Vascularity, pulmonary, congenital 747.39

Virilism *(adrenal) (female) NEC* 255.2
  with
    3-beta-hydroxysteroid dehydrogenase defect 255.2
    11-hydroxylase defect 255.2
    21-hydroxylase defect 255.2
      3-beta-hydroxysteroid dehydrogenase defect 255.2
      11-hydroxylase defect 255.2
      21-hydroxylase defect 255.2

Wandering
  in diseases classified elsewhere V40.31

Wet
  lung (syndrome)
    adult 518.52

Woillez's disease *(acute idiopathic pulmonary congestion)* 518.52

Wound, open (by cutting or piercing instrument) (by firearms) (cut) (dissection) (incised) (laceration)
  (penetration) (perforating) (puncture) (with initial hemorrhage, not internal) 879.8
  anus 863.89
    complicated 879.7
Blast (air) in war operations E993.9 from nuclear explosion - see War operations, injury due to, nuclear weapons
War operations (during hostilities) (injury) (by) (in) E995.9 blast (air) (effects) E993.9 from nuclear explosion - see War operations, injury due to, nuclear weapons
<table>
<thead>
<tr>
<th>Substance</th>
<th>Poisoning</th>
<th>Accident</th>
<th>Therapeutic</th>
<th>Suicide</th>
<th>Assault</th>
<th>Undetermined</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cleaner, cleansing agent, NEC <em>type not specified</em> of paint or varnish</td>
<td>989.89</td>
<td>E861.9</td>
<td>-</td>
<td>E950.9</td>
<td>E962.1</td>
<td>E980.9</td>
</tr>
<tr>
<td>specified type NEC</td>
<td>982.8</td>
<td>E862.9</td>
<td>-</td>
<td>E950.9</td>
<td>E962.1</td>
<td>E980.9</td>
</tr>
<tr>
<td></td>
<td>989.89</td>
<td>E861.3</td>
<td>-</td>
<td>E950.9</td>
<td>E962.1</td>
<td>E980.9</td>
</tr>
</tbody>
</table>

Key: Bold – Add; Bold Strikeout – Delete; Bold Underline Italic – Revise